Clinical Trial Update: Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating disitamab vedotin with sintilimab and XELOX as perioperative treatment for resectable gastric cancer with HER2 overexpression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Sintilimab (sintilimab)
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN